New methods for molecular diagnosis are now available in oncology thanks to the discovery of circulating tumor DNA molecules in the plasma of cancer patients. By utilizing blood samples, rather than traditional tissue sampling, clinical practice is on the verge of new discoveries from the analysis of cell-free DNA (cfDNA). The method, known as a "liquid biopsy", consists of analyzing therapeutic targets and drug-resistant conferring gene mutations in circulating tumor cells (CTC) and cell-free circulating tumor DNA (ctDNA). These are subsequently released from primary tumors and metastatic deposits into the peripheral blood. The advantages of the method can be observed in the diagnosis, but also in the choice of treatment for solid tumors (e.g. non-small cell lung carcinomas [NSCLC]). In order to interpret the results, an understanding of the biological characteristics of circulating tumor DNA is required. Currently there is no consensus as to how a liquid biopsy should be conducted. In this review, we will assess the pros of ctDNA as analytes in peripheral blood samples and its impact on clinical applications in solid tumors and hematological malignancies. We will also address practical issues facing clinical implementation, such as pre-analytical factors. Moreover, we will emphasize the open questions that remain when considering the current state of personalized medicine and targeted therapy.
Introduction
There are a number of factors that result in a diagnosis of malignancy, for example, clinical presentation, radiology, biochemical assays and the histopathological analysis of tumor tissue.
Over the last decade, molecular diagnostic tests have become increasingly popular, with a preference for the use of a histological biopsy. However, due to limited access to the tumor, attaining a tissue sample for histological analysis is often difficult. As a consequence of this, liquid biopsies have become critical both for diagnosis, but also when monitoring the cancer patient. As well as blood, other bodily fluids can be utilized in a liquid biopsy: for example, urine, stool samples, cerebrospinal fluid, saliva, pleural fluid and ascites are all potential sources of tumor-derived material [1] [2] [3] . Five important types of liquid biopsies exist: circulating tumor cells (CTCs), circulating endothelial cells (CECs), tumor-educating platelets (TEPs), exosomes and circulating tumor DNA (ctDNA) ( Figure 1A) . This review will address the use of circulating tumor DNA in the field of medical oncology.
Cell free DNA (cfDNA) vs. ctDNA
During normal physiological functioning, a continual process of cell degradation takes place in almost every tissue as a part of cell turnover. There are two major processes of cell degradation: necrosis and apoptosis ( Figure  1B ). Apoptotic and necrotic remnants are typically cleared by macrophages. However, during cell degradation, small fragments of cell content are released into circulation for renal clearance. These DNA strands disintegrate and are shed into the peripheral blood as shorter fragments. Apoptosis produces DNA fragments of ~180 base pairs (bp) (and multiples of this), whereas necrosis results in much larger fragments (>1000 bp). Both types of fragment sizes can also be observed in the blood of cancer patients [4] . Typically, patients with cancer have higher levels of circulating cfDNA than healthy individuals [5] [6] [7] . As the tumor increases in volume, cellular turnover speeds up and therefore the number of apoptotic and necrotic cells rises [4, 8] . The concentration of cfDNA in the bloodstream depends on the location, size and vascularity of the tumor, which might also account for the wide variability often seen in the levels of cfDNA.
The main predictor for the sensitivity of a plasma genotyping assay is the concentration of tumor-derived cfDNA found in the plasma. This is calculated by the relative rate that tumor cells release DNA into circulation, compared to the rate of elimination through renal clearance. The procedure of cfDNA shedding is not completely understood, but theories have been put forward relating it to aspects of tumor biology such as mitotic rate, necrosis and vascularization multiplied by the total number of tumor cells present [4, 8] .
The detection of somatic mutations in cfDNA is its first and most significant application as a biomarker, due to its high sensitivity in distinguishing ctDNA from typical fragments (cfDNA).
It has been suggested that the results from ctDNA mutations may demonstrate a more accurate "real-time" mutation profile of the tumor(s), compared to the retrospective study of formalin-fixed, paraffin-embedded (FFPE) tissue extracted from biopsies or surgeries [9] , due to the release of tumor DNA into circulation during cell turnover [10] . Both the ability to track dynamic changes in tumor biology during treatment and insights into tumor heterogeneity have been made possible by cfDNA analysis.
Technical aspects of cfDNA analysis
Previous studies have demonstrated a wide variation in the concentration of cfDNA, ranging from a few nanogram (ng)/mL to several thousand ng/mL [11] . There are possible methodological reasons for this, for example, potential bias when selecting patients, but also differences in the technical methods implemented when extracting and quantifying cfDNA. Currently, there is no standard operating procedure (SOP) for cfDNA analysis. Moreover, the timing of sampling is also a critical factor. For instance, if plasma samples are collected at suboptimal times, such as during therapy, the concentration of ctDNA will be at its lowest. The probability of key alterations decreases as the ctDNA fraction approaches the detection limit of current technologies.
The major obstacles to clinical application consist of the lack of pre-analytical and analytical consensus surrounding cfDNA. For example, the type of matrix used, storage conditions and handling of the blood samples all are factors which impact cfDNA concentration and fragmentation. We will summarize relevant pre-analytical factors that have been agreed upon below.
Circulating DNA (both cf-and ct-) is vulnerable to degradation due to its small size and simplistic structure. This is magnified by the presence of nuclease activity (DNAse I or II) in the blood, which can be up to as 100 × more in urine samples [12] . ctDNA has a comparatively short half-life of approximately 2 h without any precautionary measures [13, 14] . Plasma is the most effective matrix type for analyzing ctDNA in the blood. For example, previous research has shown that the concentration of cfDNA is higher in serum than in plasma for identical blood samples, which has been attributed to leukocyte lysis that may occur during clotting [15] . The quantity of normal DNA acquired through leukocyte lysis is much lower in plasma, which is exacerbated further when the blood is placed in collection tubes containing a leukocyte stabilizer [16, 17] . K 3 EDTA is the preferred anticoagulant when handling ctDNA, and preservation tubes can be used for up to 6 h prior to plasma isolation. Previous research has shown that the processing period can be extended up to 48 h through the use of leukocyte stabilization tubes (e.g. Streck or CellSave tubes) without comprising the detection or quantification of ctDNA [16, 18, 19] . This has been demonstrated in the field of fetal cfDNA analysis by Hidestrand et al. [20] . No significant difference was found in cfDNA concentration for samples shipped in EDTA collection tubes compared to those in so-called cell-free DNA leukocyte stabilization collection tubes which allowed for immediate processing. However, there is also evidence that cfDNA levels in blood samples extracted from cellfree DNA™ blood collection tubes remained stable for up to 14 days at room temperature. This stabilization period decreased when blood was drawn from K 3 EDTA collection tubes (see Fernando et al. [21] ).
The impact of leukocyte lysis can be minimized by removing the cellular compartment through either filtration or centrifugation once the blood is drawn. This is either implemented as a one-step low centrifugation protocol or a two-step combined approach (low speed, followed by high speed) [18, 22, 23] . Previous research has indicated a preference for the two-step protocol.
A recent review on pre-analytical variables for ctDNA collection noted that the impact of storage period and the temperature of unprocessed whole blood is variable [24] . On the one hand, storing frozen plasma prior to DNA isolation seems to have no effect on subsequent ctDNA analysis [24] . While on the other hand, DNA degradation and a decrease in the detection of ctDNA can occur from multiple freeze-thaw cycles [11, 22] .
A wide range of accessible molecular techniques exist for the detection and analysis of various DNA mutations. These range from real-time polymerase chain reaction (PCR) of hot-spot mutations to targeted mutationsequencing methods. One of the major technical challenges to be overcome, regardless of the chosen method, is the detection and identification of the large range of mutations present in ctDNA, due to it reflecting only a small amount of total cfDNA (<1.0%) [13, 14] . As the amount of ctDNA nears the detection limit of currently available methods, confidence in the existence of key alterations decreases. This must be considered during the interpretation of clinical cfDNA tests. Highly sensitive and specific methods have been developed in the past year which allow for the detection and enumeration of unique mutant variants in complex DNA mixtures. Examples include digital droplet PCR (ddPCR) [25] , beads-emulsion-amplification and magnetics (BEAMing) [26] and pyrophosphorolysis-activated polymerization (PAP) [27] . A limitation of these PCR-based methods is that they are only capable of locating hotspot mutations in a small number of genes and cannot address the full spectrum of mutations that may emerge from acquired resistance due to targeted therapy. A promising development has recently been put forward by the group of De Carvalho. A sensitive, immunoprecipitation-based protocol was developed to analyze the methylome of small amounts of cfDNA. It can also distinguish between patients with a tumor and healthy controls using large-scale DNA methylation adaptations that were enriched with tumorspecific patterns [28] .
Another technical hurdle to be overcome is the required analytical sensitivity that has not yet been implemented in diverse mutation-based ctDNA detection methods. Even with highly sensitive techniques associated with detecting ctDNA, the overall result is confined by the inherent problems caused by the inadequate amounts of input DNA copies available for analysis [13, 29] . Outcomes suffer from statistical sampling errors and a reduction in the number of clinically relevant targets that can be utilized when only a few nanograms of circulating DNA are available. The scarcity of input materials acts as a "glass ceiling" in liquid biopsy because, even with improvements in the analytical sensitivity of molecular techniques, they cannot overcome the limitation from DNA input [30] . There are methods that act as a work-around to this issue; for example, duplex PCR, where two targets are analyzed per reaction, and sample pre-amplification both enable an increase in the number of tests to be performed while simultaneously reducing the sample size prerequisite [31] .
Lastly, choosing the right panel of cancer-specific genomic aberrations is crucial and highly dependent on its clinical application. For example, when utilized for the screening of cancer patients, or for the early detection of disease in "healthy" individuals, the genomic aberrations in a single patient are unknown [32] .
Liquid biopsy vs. the gold standard (the tissue biopsy)
The methodological standard for initial pathological diagnosis and molecular testing remains the tissue biopsy. It grants both a histological interpretation and the assessment of non-DNA based alterations, for instance, in the expression of hormone reception or other proteins.
Together, these play a larger role in informing diagnoses and treatment decisions. However, significant issues in acquisition and utility remain. Access to some tumors can only be made through fine-needle aspirates (FNAs) (e.g. lung cancer) leading to too little material for genotyping. Whereas, obtaining samples from separate medical centers can be problematic [33] . Next to this, biopsies have many administrative downsides: they are difficult to schedule, increase the cost of patient care and are an uncomfortable and invasive procedure that often do not significantly impact the outcome. Repeated tumor biopsy is most effective for evaluating genetic changes in, for example, lung cancers being treated with targeted therapies. But this is not always practical and often cannot be performed more than once. Finally, and most significantly, biopsies do entail clinical complications. Adverse event rates were shown to be 17.1% and 1.6% for thoracic biopsies and abdominal/pelvic sampling, respectively, by Overman and co-workers [34] . In contrast, liquid biopsies are more favorable and entail a minimal procedural risk. Both peripheral blood (minimally invasive) and urine (non-invasive) can be used for ctDNA analysis [12, [35] [36] [37] . Large-scale control studies have demonstrated high concordance rates of between 80% and 90% for plasma and tissue samples extracted simultaneously, especially with regard to alterations in key driver genes [38, 39] .
A substantial benefit of liquid biopsies relates to the better quality of the DNA. For histopathology, the typical procedure is formalin fixation and/or paraffin embedding of the tissue. Formalin fixation results in cross-linking effects of nuclear proteins, while paraffin embedding may result in coagulation of histones due to processing temperatures exceeding 50 °C. Both of these processes are not included in the procedure for liquid biopsy, and as such, this reduces the odds of inferior DNA quality. Moreover, the entire process in histopathology has a much longer turnaround than liquid biopsy. This is due to additional pre-analytical steps that are used to isolate the DNA from the formalin fixtures and paraffin embeddings. On top of the required macro-dissection needed to extract enough tumor content, the turnaround can be as much as 25-27 days in histopathology, compared to just 10-12 days for a liquid biopsy.
More is now understood about tumor diversity, both with tumors derived from different patients (intertumor heterogeneity) but also that within individual tumors (intratumor heterogeneity; Figure 2A ) thanks to the largescale sequencing analysis of solid cancers [40] [41] [42] . It is now widely accepted that tumors comprise multiple genetically distinct subclones which grow following a pattern of branched evolution [43] . This type of intratumor heterogeneity is partially responsible for treatment failure and drug resistance [44] [45] [46] . Gerlinger et al. demonstrated that a single tumor biopsy specimen can display a sub-section of genetic aberrations (including mutations, allelic imbalance and ploidy) which are present in the tumor as a whole [44] . Intratumor heterogeneity can have significant ramifications for personalized medicinal approaches which depend on single tumor biopsy samples as a window to tumor mutational landscapes. On top of this, the mutation profile of ctDNA is subject to change with time and treatments [47, 48] . A more comprehensive representation of the mutational landscape that persists for the duration of the patient's disease may be obtained from ctDNA-analysis of liquid biopsies.
Previous research has shown that within concordance studies ctDNA false positives are typically tissue NGS false negatives. The difference in genomic alterations that is demonstrated in cfDNA, but not in tissue samples, can be due to spatial and temporal tumor heterogeneity ( Figure 2B ). This is especially so for older biopsy tissues, which could also relate to tumor evolution [49] . Histological biopsies provide a snapshot of the intratumor heterogeneity at a particular time window, but can give little information on the possible evolutionary routes subclonal populations may take [43] . Due to the noninvasive nature of the liquid biopsy, it is possible to take temporal measurements of the total tumor burden, in addition to classifying specific mutations that arise during therapy [43, 50] . Thompson et al. demonstrated that for patients with NSCLC, plasma-based ctDNA analysis is a viable non-invasive means of identifying the patient, through the acquisition of resistant mutations during first-line therapy with tyrosine kinase inhibitors (TKIs). This can act as a gauge for switching to second-and third-line TKIs or cytotoxic chemotherapy if no suitable mutation is found [51] .
A critical issue, affecting the sensitivity of the liquid biopsy, is that DNA is not released into circulation by all tumors. Previous results have found that approximately 15% of patients with metastatic cancer do not have enough ctDNA for the mutational profiling of plasma, however, this percentage varies given tumor type and burden [52, 53] . Bettegowda and colleagues indicated that patients with stage III ovarian or liver cancer, those with metastatic cancers of the pancreas, bladder, colon, stomach, breast, liver, esophagus, prostate, head or neck, as well as those with melanomas, demonstrate detectable levels of ctDNA. Yet, tumors located on the central nervous system and those with mucinous features demonstrate detectable levels of ctDNA inconsistently. It is possible that physical obstacles, for example, the blood-brain barrier or mucin, may hinder ctDNA from entering circulation [50] .
The clonal hematopoiesis of indeterminate potential (CHIP) is another reason for varied results from tumor genotyping and plasma cfDNA. The majority of cfDNA (90%) in healthy individuals originates from blood cell debris [54] . Genovese et al. demonstrated, through the use of NGS, that 10% of healthy, elderly individuals harbored somatic mutations in their cfDNA [55] . Hematopoietic clone-derived somatic mutations are very common, with an average mutation rate of around two to six mutations/1 M bases [56] , including "driver mutations" and "passenger mutations" [57] . The most commonly mutated gene in both WBC and cfDNA was found to be the NPM1 gene, which is a gatekeeper for leukemia [54] . However, the absolute conversion risk from clonal hematopoiesis into a hemato-oncologic disease was a modest 1.0% per year [55] .
Clinical applications of the liquid biopsy
There are a number of advantages to the liquid biopsy: it is a non-invasive method with a relatively short turnaround, it provides a comprehensive perspective of tumor heterogeneity, allows for an accurate snapshot of real-time tumor genomics and also the ability to foresee the evolution of the tumor using serial sampling during therapy. These promising aspects all converge into four major clinical applications, which are discussed below.
Screening and early detection of cancer
Tried and tested biomarkers for the early detection of cancer are urgently needed, especially for tumors that are typically discovered at later stages (e.g. lung and pancreatic cancers). A possible biomarker would need a high specificity combined with a high sensitivity. Due to the high error rate of DNA sequencing methods, the identification of rare tumor-specific somatic mutations from liquid biopsies is inadequate. Even with recent developments in the sensitivity of the technologies used to detect and analyze ctDNA, a sound test for early cancer detection remains elusive. For example, utilizing a blood test for widespread population screening would necessitate extraordinary levels of specificity. Dharajiya and colleagues recently showed that when analyzing the blood of a large cohort of healthy, control patients (n = 450,000) for non-invasive prenatal testing (NIPT), an abnormal genomic profile was found for 10 out of 100,000 cases. This was mainly attributed to a malignant maternal tumor and is not consistent with fetal abnormalities [58] .
Krimmel and colleagues showcased a sequence of methods that increase the sensitivity of the liquid biopsy. Through the incorporation of a duplex sequencing technique, which allows for the molecular tagging of both strands of DNA independently, rare cancer cells in peritoneal fluid were detectable. The outcome provided confirmation of widespread, low frequency, age-dependent somatic TP53 mutations in non-cancerous tissue. Cancers were identified separately from controls with 82% sensitivity and 90% specificity from the total burden of TP53 mutations [59] .
Localizing a cancer to a specific organ from a positive liquid biopsy test may present a challenge, as many cancer types share common gene mutations such as EGFR, KRAS, TP53 or BRAF.
Stratification and real-time monitoring of treatment
A relationship exists between the size of the tumor and the amount of necrosis. It is from these necrotic areas that tumor DNA is believed to be released into circulation. Therefore a natural assumption is that the amount of ctDNA could be linked to tumor burden [60] . Previous results indicating increased ctDNA levels in advancedstage patients, compared to early-stage, support this hypothesis [46, 50, 61] . For instance, a linear relationship between tumor volume and ctDNA plasma variant allele frequency (VAF) exists in NSCLC [62] . Moreover, Chaudhuri et al. reported a high correlation between the pre-treatment concentration of ctDNA and the metabolic tumor volume in patients with lung cancer [63] .
The short half-life of cfDNA in circulation (approximately 2 h) is an advantage when measuring real-time tumor burden in response to therapy. Comparatively, many standard serum tumor markers (e.g. carcinoembryonic antigen [CEA] and cancer antigen 125 ) that are in current clinical usage have half-lives of days to weeks. Although a number of studies have shown a temporary increase in the release of ctDNA after starting treatment, levels drop dramatically after 1-2 weeks due to the response [2] .
Repeated analyses over the course of the treatment period are possible with liquid biopsies -which can also inform treatment responses and indicate the emergence of resistance in real time. Early adjustments in ctDNA during chemotherapy are associated with treatment response at initial re-staging, according to Tie et al. Serial ctDNA measurements could be integrated with the results from routine imaging-based assessments when evaluating the disease bulk and the response to chemotherapeutic agents in order to give new insights [64] . From the colorectal cancer study by Diehl and colleagues, they demonstrated that ctDNA was observable in all patients prior to surgery, and that serial blood sampling showcased fluctuations in ctDNA levels, correlating to the extent of surgical resection. In addition, patients with discernible ctDNA levels after surgery typically relapsed within 1 year [14] . With technologies for cfDNA monitoring becoming increasingly accessible and cost effective, their potential to detect early indications of a response or progression may become critical for clinical management. The detection of postoperative residual disease by means of a sensitive liquid biopsy technique could spare cured patients the need to undergo potentially toxic, additional chemotherapy.
MRD detection
Several recent studies have shown that ctDNA extracted after the completion of curative therapies can act as an indicator of patients who have evidence of residual, radiographically occult cancer [63, 65, 66] . Tracking ctDNA mutations with ddPCR can identify MRD in patients with breast cancer, whilst also allowing for the earlier identification of patients at risk of tumor relapse [65] . Chaudhuri and colleagues took this further by showing that the detection of ctDNA prior to radiographic progression is possible in patients treated for localized lung cancer. This was extended to ctDNA mutation profiles that are associated with positive responses to TKIs or immune checkpoint blockades [63] . Similar findings in patients with stage II colorectal cancer have also been found [66] .
Identification of therapeutic targets and resistance mechanisms
The efficacy of targeted drugs is influenced by mutations in genes encoding therapeutic targets or downstream signaling proteins. For the past few years, significant advancements have been made in the discovery of new biomarkers, such as activating mutations in the epidermal growth factor receptor (EGFR) [67] which affect anti-EGFR therapy in lung cancer, and the Kirsten rat sarcoma viral oncogene homologue (KRAS) gene. The former mutation affects a downstream protein of the EGFR block, and has a crucial role in the anti-EGFR therapy for colorectal cancer (CRC). Currently, oncogenic mutations in KRAS and NRAS, affecting approximately 55% of CRC patients and considered a predictor of a lack of response to anti-EGFR therapy (e.g. cetuximab and panitumumab), are periodically assessed in tumor specimens [68] . The tracking of clonal dynamics of distinct resistant subclones is made possible by the analysis of cfDNA, both during sequential therapy and even after discontinuation. Siravegna et al. showed that the emerging RAS mutations during anti-EGFR therapy in patients with CRC can become undetectable in cfDNA after the end of EGFR-directed therapy, and that a large number of these patients may benefit from a reintroduction of anti-EGFR therapy [69] .
Liquid biopsy becomes especially valuable during the numerous searches for early evidence of recurrence or resistance once a patient undergoes targeted therapy with multiple metastases. Insights into the temporal measurements of the total tumor burden, as well as identification of specific therapy-derived mutations can all be obtained [14, 70, 71] . Resistance is a common occurrence for nearly all tumor treatments due to tumor heterogeneity, clonal evolution and selection. For example, the most prevalent genetic alterations in NSCLC, such as exon 19 deletions and the L858R point mutation in exon 21, account for up to 90% of EGFR mutations in the clinic [72] . The classification of small molecule TKIs against EGFR can be separated into first/second generation (erlotinib, afatinib and gefitinib) and third generation (osimertinib). Accounting for up to 50%-60% of cases, the EGFR T790M mutation is the most frequent mechanism of acquired resistance to first and second generation EGFR TKIs [73] [74] [75] . The testing for T790M at acquired resistance with an approved test method has been integrated into standard patient care, thanks to the regulatory approval of osimertinib in the US, Europe and Japan. Clinical outcomes of patients demonstrating T790M-positive plasma genotyping results with osimertinib (liquid biopsy) are comparable to the outcomes observed when treating T790M-positive tumor genotyping results [76] .
Future challenges of the liquid biopsy
The implementation of liquid biopsy during targeted therapies has noticeably altered cancer treatments over the past 10 years. However, new issues and challenges have arisen, such as tumor heterogeneity and molecular evolution, the costs and potential morbidity of biopsies, a lack of effective drugs against most genomic aberrations, technical limitations of molecular tests, and reimbursement and regulatory hurdles [67] .
A significant technical challenge lies in increasing test sensitivity for the detection of even lower levels of ctDNA in bodily fluids. One approach is to compensate the reduced number of input molecules by also testing a larger amount of mutations, and subsequently calculating the minimum number of detected mutations required to classify a plasma sample as tumor positive [62, 77] . A different take is to measure and incorporate multiple parameters into the test. Sefrioui et al. reported both enhanced sensitivity and specificity in the diagnosis of pancreatic cancer through the use of a range of protein biomarkers (CA19-9, TIMP1 and LRG1) during ctDNA analysis [78] .
Conclusions
The field of precision oncology is increasingly adapting to liquid biopsies as a non-invasive, quick, easy and repeatable procedure that allows for the monitoring of disease courses. Real-time ctDNA analysis has the potential to become a valuable tool within precision oncology, both in clinical trials and eventually into standard clinical management. The method affords the ability to detect treatable target mutations, as well as achieving more comprehensive insights into tumor and temporal heterogeneity. This review has highlighted both the advantages seen in incorporating liquid biopsies, but also the numerous hurdles that must be overcome before wide-scale implementation into precision medicine can occur.
